You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 翰宇藥業一字漲停 與中國科學院微生物研究所合作開發新型冠狀病毒多肽鼻噴劑藥物
格隆匯 11-15 10:10
格隆匯11月15日丨翰宇藥業一字漲停,近12個交易日累計漲幅已經翻倍,現報10.34元創約一年半新高,總市值95億元。翰宇藥業公佈,基於近一年來公司與中國科學院微生物研究所在多肽新冠藥物的技術交流與合作,雙方擬合作開發新型冠狀病毒多肽鼻噴劑藥物,其中中國科學院微生物研究所擬將“一種抗新型冠狀病毒的多肽及其應用”的專利申請技術中6條多肽序列以全球獨佔許可方式許可給翰宇藥業,項目總金額6500萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account